Benign form of myasthenia gravis after nivolumab treatment.
Department "G. F. Ingrassia", Section of Neurosciences, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
Giorgia
G
Sciacca
Department "G. F. Ingrassia", Section of Neurosciences, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
Alessandra
A
Nicoletti
Department "G. F. Ingrassia", Section of Neurosciences, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
Luigi
L
Rampello
Oncology Unit, Policlinico Hospital, Catania, Italy.
Laura
L
Noto
Oncology Unit, Policlinico Hospital, Catania, Italy.
Hector J Soto
HJ
Parra
Department "G. F. Ingrassia", Section of Neurosciences, University of Catania, Via Santa Sofia 78, 95123, Catania, Italy.
Mario
M
Zappia
D000230:Adenocarcinoma / Q000188:drug therapy; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001932:Brain Neoplasms / Q000188:drug therapy; D006801:Humans; D008297:Male; D009157:Myasthenia Gravis / Q000139:chemically induced* / Q000473:pathology; D000077594:Nivolumab
D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab